BioSpace News Archive

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes T hrough I mproving C ontractility in H eart F ailure), the Phase 3 pivotal cardiovascular outcomes trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), has been accepted for presentation in a virtual Late Breaking Clinical Trial session at t

Perrigo Company plc (NYSE; TASE: PRGO) today announced a voluntary U.S. nationwide recall of albuterol sulfate inhalation aerosol to the retail level after previously halting production and distribution. These actions are being taken out of an abundance of caution as a result of complaints that some units may not dispense due to cloggin

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood Institute (N

Apnimed, a clinical-stage pharmaceutical company focused on developing medicines to treat sleep apnea and related disorders, today announced the results of a Phase 1 study for a component of the company’s lead combination drug candidate, AD109, which i

Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit taking place September 21 – 23, 2020.

XWPharma (formerly XW Laboratories), a biopharmaceutical company dedicated to the discovery and development of therapeutics that apply novel platform chemistry to time-regulated neurobiology, today announced it completed a $40 million Series C financing

Cardiff Oncology, Inc. (Nasdaq: CRDF), today announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response of onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC) patients at the

Clinical Study Investigates Host Response-Related Biological Processes that Relate to Immunotherapy Treatment Resistance in NSCLC Patients [17-September-2020] BINYAMINA, Israel , Sept. 17, 2020 /PRNewswire/ -- OncoHost , a global leader in host response profiling for improved personalized cancer therapy, announced today that its research on the use of its plasma prot

Raziel Therapeutics, a Pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market announces licensing of its disruptive technology, RZL-012, to Fosun Pharma for milestone

Flu vaccination is especially important for people who are most at risk of flu complications, namely the 200 million people over the age of 50 and individuals who have chronic health conditions